PolicyChanges tracks payer policy changes for medical practices and tells you what to do before they take effect.

Create a free accountPolicy Monitoring is free. No card required.
← Back to list
AetnaAll Plans · Coverage · Medical Policy · OB-GYN, OncologyMedium impact

Endometrial Cancer Screening, Diagnosis, and Prognosis (CPB 0769, reviewed 2025-10-03)

Effective date
Not stated in the notice
Identified
Aug 14, 2026

Summary

Aetna considers endometrial biopsy medically necessary for the diagnostic evaluation of abnormal uterine bleeding in women suspected of having endometrial hyperplasia or endometrial carcinoma, and for endometrial cancer surveillance in women with Lynch syndrome. The endometrial brush (Tao brush) is an acceptable alternative to a suction curette such as the Pipelle for medically necessary sampling. Sentinel lymph node mapping is medically necessary for pathologic evaluation and surgical staging in persons with endometrial cancer and endometrial intraepithelial neoplasia (EIN), while endometrial biopsy for screening and many biomarker and genetic tests for endometrial cancer are experimental, investigational, or unproven.

Get alerts when payers change rules like this one

We check Aetna and other payers every day and email you when a change matches your specialty and state.

Get Aetna alertsPolicy Monitoring is free. No card required.

What to do

Action · 5 steps
01Billing team: Bill endometrial sampling (CPT 58100, 58110 and 58558) only for the covered indications in the policy, and bill sentinel lymph node mapping (CPT 38792 and 38900, HCPCS C7503) only for pathologic evaluation and surgical staging of endometrial cancer and EIN when the selection criteria are met.
02Use ICD-10 Z15.04 for Lynch syndrome surveillance, which the policy covers when the selection criteria are met.
03Do not bill Z12.79 for screening for endometrial cancer, because the policy does not cover it.
04Do not bill CPT 78195, 81321, 81322, 81323 or 86305 for the indications listed in the policy, because they are not covered for those indications.
05Do not bill the experimental, investigational or unproven tests listed in the policy, including endometrial biopsy for screening, PTEN immunohistochemistry for the differential diagnosis of benign and pre-malignant endometrial hyperplasia, blood AMH level for screening and diagnosis, and circulating YKL-40, serum HE4 and urine microRNAs for diagnosis.

Codes mentioned

38792389005810058110585587819581321813228132386305C7503C54.1C54.9D06.0D07.0N85.00N85.02N92.1N92.4N92.5N93.8N93.9Z15.04Z12.79

Original notice

Endometrial Cancer Screening, Diagnosis, and Prognosis (CPB 0769, reviewed 2025-10-03)
aetna.com · Always check the source before changing claims.
View original ↗

Related policy hubs

Summaries are AI-assisted. Always confirm against the original payer notice.

What is PolicyChanges

One workspace for payer rules, prior auth, coding and compliance

Medical practices use PolicyChanges to catch payer changes before they cause denials. Every change is summarized in plain English, with the codes involved, the date it takes effect and what to do.

Start freePolicy Monitoring is free. No card required.
Get alerts for changes like thisPolicy Monitoring is free. No card required.Create a free account